Overview
Acute demyelinating polyneuropathy involves rapid onset of neurological deficits due to demyelination of peripheral nerves, often resembling Guillain-Barré syndrome. It is characterized by an inflammatory response that may correlate with disease activity and potentially influence cardiac outcomes, including arrhythmias 1.Diagnosis
Clinical presentation of acute onset weakness, sensory disturbances, and potential autonomic dysfunction.
Electrophysiological studies (nerve conduction studies, electromyography) showing demyelination patterns.
Cerebrospinal fluid analysis often reveals albuminocytologic dissociation (elevated protein levels with normal cell count).
Exclusion of other causes through imaging and laboratory tests 1.Management
First-line treatments: Intravenous immunoglobulin (IVIG) or corticosteroids to modulate the immune response.
Plasma exchange (PE): Considered for severe cases or when other treatments are ineffective 1.
Supportive care: Management of respiratory complications, pain control, and monitoring for autonomic dysfunction.
Cardiac monitoring: Increased vigilance for arrhythmias due to potential inflammatory contributions 1.Special Populations
Elderly: Higher risk of complications; tailored supportive care and close monitoring essential 1.
Comorbidities: Presence of other conditions may complicate management; individualized treatment plans required 1.Key Recommendations
Monitor inflammatory markers to assess disease activity and potential arrhythmia risk in patients with acute demyelinating polyneuropathy (Evidence: Moderate) 1.
Initiate first-line treatment with IVIG or corticosteroids for acute demyelinating polyneuropathy (Evidence: Expert opinion) 1.
Consider plasma exchange in severe cases or when initial treatments fail (Evidence: Expert opinion) 1.References
1 Yalta K, Yalta T, Turgut OO, Yılmaz MB, Tandogan I. Cytokines: potential contributors to arrhythmogenesis in demyelinating syndromes?. International journal of cardiology 2011. link